Abstract 12545: Adoption of Sacubitril/Valsartan in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The AHA Get With The Guidelines - Heart Failure Registry

Jacob B Pierce,Zhen Li,Melissa Greiner,STEVEN LIPPMANN,Natalie C Hardy,Xian Shen,Mark Stampehl,Robert J Mentz,Larry A Allen,Pamela Peterson,Gregg C Fonarow,Emily C Obrien,Stephen J Greene,Jacob B PierceZhen LiMelissa GreinerSTEVEN LIPPMANNNatalie C HardyXian ShenMark StampehlRobert J MentzLarry A AllenPamela PetersonGregg C FonarowEmily C ObrienStephen J GreeneHillsborough,NCDuke Univ,Durham,NCDuke Univ Sch of Medicine,Durham,NCNOVARTIS PHARMACEUTICAL CORPORATION,East Hanover,NJNOVARTIS PHARMACEUTICAL CORPORATION,Columbia,MODuke Clinical Rsch Institute,Durham,NCUNIVERSITY COLORADO DENVER,Aurora,CODENVER HEALTH MEDICAL CENTER,Denver,COUCLA MEDICAL CENTER,Los Angeles,CADuke Clinical Rsch Institute,Durham

DOI: https://doi.org/10.1161/circ.146.suppl_1.12545

IF: 37.8

2022-11-01

Circulation

Abstract:Circulation, Volume 146, Issue Suppl_1, Page A12545-A12545, November 8, 2022. Introduction:In February 2021, the US FDA expanded the indication for sacubitril/valsartan (S/V) to include patients with heart failure (HF) with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), with benefits most evident among patients with EF below normal. However, the adoption of S/V among patients with EF >40% in US clinical practice is unknown.Methods:We identified hospitalizations for HF in the AHA Get With The Guidelines®-Heart Failure registry between January 2016 and December 2021 among patients with EF >40% to 60%, and not receiving dialysis. We evaluated prescription of S/V at discharge, and compared patient characteristics among those prescribed and not prescribed S/V. We also assessed temporal trends in S/V discharge prescription before and after FDA label expansion. We considered prescriptions of S/V on or after March 1, 2021, to have occurred after FDA label expansion.Results:Among 151,763 hospitalizations for patients with EF >40-60%, 3,001 (2.0%) included a prescription for S/V at discharge. Patients prescribed S/V were more likely to be younger, male, Black race, and privately insured compared with those not prescribed S/V(Figure, Panel A).Those prescribed S/V had lower EF (median 48% [Q1 45%, Q3 55%] versus 55% [50%, 58%]), lower blood pressure, lower rates of kidney disease, and higher rates of ischemic HF and diabetes. Following FDA label expansion, discharge prescription of S/V in the study population more than doubled compared with earlier years (4.3% vs 1.6%; p 40-60% has significantly increased following FDA label expansion, use of S/V among these patients remains low. Compared with patients not prescribed S/V, patients with EF>40-60% receiving S/V at discharge have a distinct demographic and clinical profile, including tendency for HFmrEF more than HFpEF.

cardiac & cardiovascular systems,peripheral vascular disease